


ELDER PHARMACEUTICALS LIMITED						
STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2014						
						(RS IN LACS)
STANDALONE						
SR.NO.	PARTICULARS	3 months ended	Previous 3 months ended	Corresponding 3 months ended in previous year	Year to date figures for current period ended	Previous accounting Period ended
		6/30/2014	3/31/2014	6/30/2013	6/30/2014	6/30/2013
		Audited	Unaudited	Audited	Audited	Audited
	INCOME FROM OPERATIONS					
a	NET SALES / INCOME FROM OPERATIONS (Net of excise duty)	9000.29	10100.52	18793.00	48070.12	122992.63
b	OTHER OPERATING INCOME	74.72	72.05	132.06	277.30	317.03
	TOTAL INCOME FROM OPERATIONS(NET)(A+B)	9075.01	10172.57	18925.06	48347.42	123309.66
2	EXPENSES					
a)	Cost of materials consumed	1253.08	985.36	1288.09	4884.40	12247.05
b)	Purchases of stock-in-trade	2367.23	4339.08	1776.50	13182.44	39346.17
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	11003.93	-777.90	3273.06	12768.37	5715.91
d)	Employee benefits expense.	3407.34	3038.77	3140.52	11638.74	15748.79
e)	Depreciation and amortisation expense	899.04	730.67	733.30	2915.77	3652.09
f)	Other expenses	5233.70	3935.02	3658.18	14683.58	23344.88
	TOTAL EXPENSES	23964.32	12251.00	13869.65	60073.30	100054.89
3	PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)	(14889.31)	(2078.43)	5055.41	(11725.88)	23254.77
4	OTHER INCOME	(389.33)	1157.62	(16.23)	1513.24	2621.76
5	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)	(15278.64)	(920.81)	5039.18	(10212.64)	25876.53
6	Finance costs	11755.39	6607.41	4364.96	26006.43	13797.34
7	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	(27034.03)	(7528.22)	674.22	(36219.07)	12079.19
8	EXCEPTIONAL ITEMS	38004.43	0.00	0.00	38004.43	508.77
9	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)	10970.40	(7528.22)	674.22	1785.36	11570.42
10	TAX EXPENSES	67.13	0.00	(3.34)	67.13	2196.66
11	NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES (9-10)	10903.27	(7528.22)	677.56	1718.23	9373.76
12	EXTRAORDINARY ITEM (NET OF TAX EXP. RS.-Lacs)	0.00	---	---	---	---
13	NET PROFIT/(LOSS) FOR THE PERIOD (11-12)	10903.27	(7528.22)	677.56	1718.23	9373.76
14	SHARE OF PROFIT/(LOSS) OF ASSOCIATES	0.00	0.00	0.00	0.00	0.00
15	MINORITY INTEREST	0.00	0.00	0.00	0.00	0.00
16	NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)	10903.27	(7528.22)	677.56	1718.23	9373.76

SR.NO.	PARTICULARS	3 months	Previous	Corresponding	Year to date	Previous
		ended	3 months	3 months	figures for	accounting
		6/30/2014	ended	ended	current period	Period
		Audited	Unaudited	Audited	Audited	Audited
		6/30/2014	3/31/2014	6/30/2013	6/30/2014	6/30/2013
17	PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)	2053.69	2053.69	2053.69	2053.69	2053.69
18	RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR	--	--	--	76502.65	75726.46
19i	EARNINGS PER SHARE (before extraordinary items) (of Rs.10/-each) (not annualised)					
	a) Basic	53.09	(36.66)	3.30	8.37	45.64
	b) Diluted					
19ii	EARNINGS PER SHARE (After extraordinary items) (of Rs.10/-each) (not annualised)	53.09	(36.66)	3.30	8.37	45.64
	a) Basic					
	b) Diluted					
A PARTICULARS OF SHAREHOLDING						
1 PUBLIC SHAREHOLDING:						
	NUMBER OF SHARES	15349156	15436656	13471572	15349156	13471572
	PERCENTAGE OF SHAREHOLDING	74.74	75.17	65.60	74.74	65.60
2 PROMOTERS & PROMOTER GROUP SHAREHOLDING						
A) PLEDGED/ENCUMBERED						
	-NUMBER OF SHARES	4666131	4666131	7024370	4666131	7024370
	-PERCENTAGE OF SHRAES(AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	89.94	91.49	99.42	89.94	99.42
	-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	22.72	22.72	34.20	22.72	34.20
B) NON - ENCUMBERED						
	-NUMBER OF SHARES	521649	434149	40994	521649	40994
	-PERCENTAGE OF SHRAES(AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	10.06	8.51	0.58	10.06	0.58
	-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	2.54	2.11	0.20	2.54	0.20
PARTICULARS		AS ON 30-06-2014				
B INVESTOR COMPLAINTS:						
	Pending at the beginning of the quarter	0				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	0				
Notes:						
1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 27th August, 2014						
2) The slump Sales Transaction with Torrent Pharmaceuticals Ltd., was completed and consummated on 29th June 2014						
3) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.						
4) Exceptional items represents:						
a) Profit from Slumpsale(Net of Tax) Rs.173431.34 lacs.						
b) Writing off of Trade receivables Rs.(32270.76) lacs.						
c) Loss on sales of Advances Rs.(103156.14) lacs.						
5) Provision for Tax includes Current tax & Deferred tax.						
6) Year to date figures are for a period 12 months whereas previous period figures are for 15 months						
7) Previous years & Quarter figures have been regrouped/rearranged when						
FOR ELDER PHARMACEUTICALS LTD						
 ALOK SAXENA MANAGING DIRECTOR & CEO						
Place: Mumbai						
Date : 27th August,2014						

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lacs)

PARTICULARS	As at Current	AS at Previous
	year Ended 6/30/2014	Year ended 6/30/2013
	Audited	Audited
A EQUITY AND LIABILITIES		
1 Shareholder's Funds		
(a) Share Capital	2053.69	2053.69
(b) Reserve and Surplus	76502.63	75726.46
(c) Pending call Money	2.97	2.97
Sub-Total Shareholders' funds		77,783.12
	78559.29	
2 Non-current liabilities		
(a) Long term borrowings	40058.86	57363.47
(b) long -term provisions	1459.57	1654.78
Sub-total _non_Current- liabilities		59,018.25
	41518.43	
3 Current Liabilities		
(a) Short- term borrowings	19,553.58	39,862.84
(b) Trade payable	3,382.52	6,805.74
(c) Other current liabilities	28,709.13	34,420.54
(d) Short -term provisions	21,854.22	2,932.72
Sub-total _Current- liabilities		84,021.84
	73499.45	
TOTAL-EQUITY AND LIABILITIES		220,823.21
	193577.17	
B ASSETS		
1 Non-current assets		
(a) Fixed assets	73,916.90	75,259.17
(b) Non -current investments	246.27	251.27
(c) Deferred tax Assets(Net)	2.85	69.97
(d) Long-term loans and advances	47,280.74	75,419.73
Sub-total -Non-current- assets		151,000.14
	121446.76	
2 Current assets		
(a) Current investments	127.00	138.50
(b) Inventories	2,789.73	15,925.97
(c) Trade receivables	8,446.73	32,836.91
(d) cash and cash equivalents	53,838.60	8,783.49
(e) Short-term loans and advances	3,076.54	8,804.76
(f) Other current assets	3,851.81	3,333.44
Sub-total -current- assets		69,823.07
	72130.41	
TOTAL ASSETS		220,823.21
	193577.17	

ELDER PHARMACEUTICALS LIMITED						
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2014						
CONSOLIDATED						
SR.NO.	PARTICULARS	3 months ended	Previous 3 months ended	Corresponding 3 months ended	Year to date figures for	Previous accounting Period
		6/30/2014	3/31/2014	6/30/2013	6/30/2014	6/30/2013
		Audited	Unaudited	Audited	Audited	Audited
	INCOME FROM OPERATIONS					
a	NET SALES / INCOME FROM OPERATIONS (Net of excise duty)	12283.06	22740.66	18424.64	100613.49	163853.06
b	OTHER OPERATING INCOME	-260.56	144.84	81.76	277.30	317.03
	TOTAL INCOME FROM OPERATIONS(NET)(A+B)	12022.50	22885.60	18506.40	100890.79	164170.11
2	EXPENSES					
	a)Cost of materials consumed	948.31	1158.14	1077.06	5291.40	12583.26
	b)Purchases of stock-in-trade	6092.89	12400.84	6830.97	47183.06	71182.21
	c)Changes in inventories of finished goods, work-in-progress and stock-in-trade	10592.64	-1424.91	-2334.03	11826.98	-130.19
	d) Employee benefits expense	3954.01	5945.87	3580.19	22190.04	23514.14
	e)Depreciation and amortisation expense	630.06	953.39	815.41	3612.55	4407.57
	f)Other expenses	5251.24	5659.36	3603.31	22328.24	29286.66
	TOTAL EXPENSES	27469.16	24692.69	13672.93	112422.27	141243.66
3	PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)	(15446.66)	(1807.19)	4933.47	(11631.48)	22926.46
4	OTHER INCOME	212.34	1272.58	225.05	2565.82	3269.88
5	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)	(15234.31)	(534.61)	5158.52	(8965.66)	26196.34
6	Finance costs	12000.78	8946.42	4780.17	27563.12	15482.59
7	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	(27235.09)	(7481.03)	378.35	(36528.78)	10713.75
8	EXCEPTIONAL ITEMS	36885.39	(289.94)	296.65	37127.33	283.03
9	PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)	9650.30	(7191.09)	674.00	595.55	10430.72
10	TAX EXPENSES	(4.87)	172.13	(2.64)	325.68	2191.56
11	NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9-10)	9655.17	(7363.22)	671.36	272.87	8239.16
12	EXTRAORDINARY ITEM (NET OF TAX EXP. RS.--Lac)	0.00	-	-	-	-
13	NET PROFIT/(LOSS) FOR THE PERIOD (11-12)	9655.17	(7363.22)	671.36	272.87	8239.16
14	SHARE OF PROFIT/(LOSS) OF ASSOCIATES	0.00	0.00	0.00	0.00	0.00
15	MINORITY INTEREST	0.00	0.00	0.00	0.00	0.00
16	NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)	9655.17	(7363.22)	671.36	272.87	8239.16

SR.NO.	PARTICULARS	3 months	Previous	Corresponding	Year to date	Previous
		ended	3 months	3 months	figures for	accounting
			ended	ended	ended	Period
		6/30/2014	3/31/2014	in previous year	ended	ended
	Audited	Unaudited	6/30/2013	6/30/2014	6/30/2013	Audited
17	PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)	2053.69	2053.69	2053.69	2053.69	2053.69
18	RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR	---	---	---	76278.21	74869.71
19	EARNINGS PER SHARE (before extraordinary items) (of Rs.10/-each) (not annualised)					
	a) Basic	47.01	(36.85)	0.41	1.33	40.13
	b) Diluted					
19I	EARNINGS PER SHARE (After extraordinary items) (of Rs.10/-each) (not annualised)	47.01	-35.85	0.41	1.33	40.13
	a) Basic					
	b) Diluted					
A	PARTICULARS OF SHAREHOLDING					
1	PUBLIC SHAREHOLDING:					
	NUMBER OF SHARES	15349156	15436656	13471572	15349156	13471572
	PERCENTAGE OF SHAREHOLDING	74.74	75.17	65.60	74.74	65.6
2	PROMOTERS & PROMOTER GROUP SHAREHOLDING					
	A) PLEDGED/ENCUMBERED					
	-NUMBER OF SHARES	4666131	4666131	7024370	4666131	7024370
	-PERCENTAGE OF SHARES (AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	89.94	91.49	99.42	89.94	99.42
	-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	22.72	22.72	34.2	22.72	34.2
	B) NON - ENCUMBERED					
	-NUMBER OF SHARES	521649	434149	40994	521649	40994
	-PERCENTAGE OF SHARES (AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	10.06	8.51	0.58	10.06	0.58
	-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	2.54	2.11	0.2	2.54	0.2
	PARTICULARS	AS ON 30-06-2014				
B	INVESTOR COMPLAINTS:					
	Pending at the beginning of the quarter	0				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	0				
Notes:						
1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 27th August, 2014						
2) The slump Sales Transaction with Torrent Pharmaceuticals Ltd., was completed and consummated on 29th June 2014						
3) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.						
4) Exceptional items represents:						
a) Profit from Slumpsale (Net of Tax) Rs. 173431.34 lacs.						
b) Writing off of Trade receivables Rs (32571.18) lacs.						
c) Loss on sales of Advances & others Rs (103732.82) lacs.						
5) Provision for Tax includes Current tax & Deferred tax.						
6) The consolidated results include the results of the wholly owned subsidiaries of the company viz. Elder International FZCO, Dubai upto 31st March 2014, Elder Biomedica EAD, Bulgaria, upto 31st December 2013 and Nutrahealth Ltd., U.K. upto 31st March 2014.						
7) Consolidated audited results of June 2014 quarter ended do not include the results of the subsidiaries in view of the note no. 6						
8) Year to date figures are for a period 12 months whereas previous period figures are for 15 months hence not comparable						
9) Previous years & Quarter figures have been regrouped/rearranged wherever necessary.						
Place:	Mumbai					
Date:	27th August, 2014					
					ALOK SAXENA MANAGING DIRECTOR & CEO	

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lacs)

CONSOLIDATED

PARTICULARS	As at Current year Ended 6/30/2014	AS at Previous Year ended 6/30/2013
	Audited	Audited
A EQUITY AND LIABILITIES		
1 Shareholder's Funds		
(a) Share Capital	2053.69	2053.69
(b) Reserve and Surplus	75278.21	74869.71
(c) Pending call Money	2.97	2.97
Sub-Total Shareholders' funds	77334.87	76,926.37
2 Non-current liabilities		
(a) Long term borrowings	54038.37	70393.69
(b) deferred tax Liabilities(Net)	497.22	290.20
(c) long -term provisions	2120.87	1654.78
Sub-total _non_Current- liabilities	56656.46	72,338.67
3 Current Liabilities		
(a) Short- term borrowings	26,466.43	44,351.04
(b) Trade payable	9,612.23	12,045.49
(c) Other current liabilities	36,895.39	40,586.32
(d) Short -term provisions	21,854.22	2,999.68
Sub-total _Current- liabilities	94828.27	99,982.53
TOTAL-EQUITY AND LIABILITIES	228819.60	249,247.57
B ASSETS		
1 Non-current assets		
(a) Fixed assets	101,237.52	96,312.66
(b) Non -current investments	183.86	188.86
(c) Long-term loans and advances	34,998.25	64,832.80
Sub-total -Non-current- assets	136419.63	161,334.32
2 Current assets		
(a) Current investments	127.00	138.50
(b) Inventories	12,798.61	24,506.93
(c) Trade receivables	16,567.65	39,814.79
(d) cash and cash equivalents	54,661.01	10,343.99
(e) Short-term loans and advances	4,195.07	9,470.42
(f) Other current assets	4,050.63	3,638.62
Sub-total -current- assets	92399.97	87,913.25
TOTAL ASSETS	228819.60	249,247.57